This is indeed great news. I would count on a 2017 product launch as they know it works, just need to fine tune the dose.
If it is true they are going to be able to up-list in the 1st qtr, then why release statements before then, as the same 45,000 shareholders will see or notice it & no one else. Cheaper battery powered cars coming anyway, so patience is a virtue.
LOL! You must stop picking on the mentally ill/ridiculously stooopid. He is a clown of clowns.
Sentiment: Strong Buy
Butter, they seem to have enough money to go for quite a while. If they can attract a BP partner on any indication, I would think dilution would minimal. That being said...we still have Dan O'conor and a few others lining their pockets, but in the end its still awfully cheap compared to the other Imuno stocks & they are in no better a position then we are.
Most positive thing I could find...except its negative. Hopefully they get their cheit together.
Excluding the impairment charge in the third quarter of 2014 and the tax benefit in the year-ago quarter, net loss in the third quarter of 2014 decreased to $2.0 million from $2.7 million last year.
You mean..stroking of course. I would think once Phase 2 gets going there will be plenty of opportunity to issue press releases. This stock always sucks during Nov-Dec anyway. I know, it sucks all the time, but like the Cubs say...wait till next year!
1st good thing I've red about New Jersey in my life! Who would have guessed I would reap a bit of personal benefit from it.
Just the blood & Cell Mnfg are worth multiple billions. Once were off the pinky sheets the company will be valued more in-line with future prospects. Very cheap right now.
Yea, broke even at 2.30 and bailed, pretty frustrating. I do think it can break $3 though...hope you get your money back.
At least it wasn't a call from credit card services!
Easy 600MM+ mkt cap by the end of 2015 with 150 new trial patients improved or stabilized vision being reported early 2016. Name change was unnecessary as Advanced Cell Tech said it all...and for better or worse had plenty of name recognition.
Congrats on the 1st post 2cow, 2015 will be a banner year for OCATA...150 patients will end the year much happier then they started it...watch & Learnt!
Sentiment: Strong Buy
I don't think I'm being unreasonable. Yes phase 1 took forever and a day, but as you know, 6 months after treatment the results are pretty clear (and pretty good). If & when they have 100 out of 150 patients with improved vision & 150 with stabilized vision there will be some pretty good value here. Everyone is as frustrated as you, but the game is hardly over. Look at it this way, you have another year to pound on management & then you'll become Mr Happy Face and start EYEing the Toyota Mirai. Maybe buy two of them, one for the wife.
Amazing it's down here with phase 2 coming in 2 months or so. With 150 patients there will be plenty of publicity and results come much sooner then in most other studies. By late 2017 they could be ready to roll. And while were waiting some advances on the blood front will give the stock an extra boost. The company will have a valuation over 600m by the end of 2015.